A novel concept of fully personalized therapeutic cancer vaccines, called Glioma Actively Personalized VAccine Consortium (GAPVAC), has been moved into the clinic. It is the first european approval for such a technology. The project is lead by two german Biotech companies Immatics biotechnologies and BioNTech, and received a €6 million grant from European Union.
The German National Authorities has approved the start of a phase 1/2 study, GAPVAC-101, which applies for the first time the concept of treating glioblastoma patients based on drugs designed and manufactured for each patient individually according to specific characteritics of their tumor and immune system.
GAPVAC is the first EU initiative aimed at clinically developing biomarker-guided actively personalized vaccines (APVACs) to treat patients with glioblastoma.
Glioblastoma is an aggressive form of brain cancer with poor prognosis which has a high unmet need and the limited treatments available today have minimal effect on overall survival. The GAPVAC consortium includes 14 organizations in Europe and the United States and is led by Immatics biotechnologies GmbH and BioNTech AG.